Study guide

1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection

Key Takeaways Explain This Topic AI

A scientific hypothesis is a falsifiable prediction that drives dose, species, endpoint, and statistics; a regulatory guideline study uses a prescribed design so an authority can compare results against a standard and historical controls.

Good Laboratory Practice is a quality system for conduct, documentation, and integrity (FDA 21 CFR Part 58; OECD GLP). It is not a test guideline and does not choose OECD 408 versus ICH M3(R2).

Chemical programs often use OECD Test Guidelines (408 90-day oral, 413 90-day inhalation, 414 prenatal developmental, 443 EOGRT, 420 acute oral, 471 Ames) plus EPA OCSPP 870 methods when the United States is the pesticide or TSCA driver.

Human pharmaceuticals are timed and scoped by ICH M3(R2), with ICH S5, S1, and S7A/S7B specifying reproductive, carcinogenicity, and safety-pharmacology packages; FDA Redbook is a food-ingredient playbook, not an IND playbook.

Pick the study that answers the decision question: portal-of-entry inhalation is not replaced by a convenient oral 90-day, and an Ames assay does not replace a two-year bioassay when the question is carcinogenic potential.

Last updated: September 2026

Why hypothesis and guideline selection sit in Domain I.A

Handbook tasks I.A.1 A–B and I.A.2 ask whether you can design a study that actually answers the question in front of you, then comply with the regulations that apply to that agent . A clean Ames plate does not tell you whether a workplace dust causes pulmonary fibrosis. A 90-day oral rat study does not, by itself, support first-in-human dosing of a small-molecule drug. DABT items in this area punish recipe thinking: “we always run OECD 408” is not a design rationale.

Scientific hypothesis versus regulatory guideline study

A scientific hypothesis is a falsifiable statement that relates an independent variable to a predicted dependent outcome in a defined system. In toxicology that often looks like: “Daily oral gavage of Compound X at 100 mg/kg/day for 28 days in Sprague Dawley rats increases hepatocellular Ki-67 labeling relative to vehicle by inducing CYP2B, not by cytotoxicity.” The protocol then locks the species, dose, route, duration, endpoints, and the a priori statistical plan (for example a two-sided trend test on the labeling index, with pairwise tests only if the trend is significant).

Elements of a usable hypothesis:

  • A population (species, strain, sex, life-stage)
  • An intervention (agent, dose/concentration, vehicle, route, duration)
  • A comparator (vehicle, sham, untreated, or positive control)
  • A measurable outcome (incidence, severity, biomarker, BMD)
  • A decision rule (what result would reject the prediction)

A regulatory guideline study still has an objective, but the objective is usually a decision question an authority already knows how to interpret: Is there a no-observed-adverse-effect level (NOAEL) after 90 oral days in the rat? Is the substance mutagenic in bacteria? Does embryo-fetal death or malformation occur in two species when dams are dosed during organogenesis? Group size, dose spacing, required tissues, and often the statistical philosophy are prescribed so results can be compared across laboratories and against historical control databases.

You may not drop thyroid histopathology on an OECD 408 because you “were not hypothesizing endocrine effects.” You also may not invent a custom two-animal, one-dose “hypothesis GLP study” and call it an ICH M3(R2) repeat-dose package. Investigative studies can and should change dose, species, or endpoints to chase a mechanism. Pivotal guideline studies change those elements only with a documented scientific or animal-welfare justification.

GLP is not a test guideline

Good Laboratory Practice (GLP) is a quality system . In the United States, nonclinical laboratory studies intended to support FDA products are described in 21 CFR Part 58 . OECD GLP Principles serve a similar function for studies meant to travel under Mutual Acceptance of Data (MAD) . GLP specifies protocol control, standard operating procedures, a Study Director , a Quality Assurance Unit , raw-data integrity, and the archive. GLP does not tell you to use 10 rats/sex/group, to necropsy the brain, or to include a recovery cohort.

Those scientific choices live in test guidelines and ICH/FDA/EPA/EMA scientific guidelines . Consequences:

A study can follow OECD 408 in design but be non-GLP (common for dose-range-finding).

A study can be GLP yet custom-designed (an investigative GLP mechanistic study).

A pivotal safety package for FDA, EPA, or an OECD MAD filing usually needs the correct scientific guideline and GLP , not one or the other.

Calling a sloppy in-life “GLP” because the bioanalytical method had a certificate of analysis is a category error. Calling a perfect GLP study “OECD 414” because rabbits were used, when dosing never covered organogenesis and fetuses were not examined, is the same error in the other direction.

Which legal-scientific driver actually owns the design?

Driver Typical agents What it decides Examples a DABT candidate should name

OECD Test Guidelines Industrial chemicals, pesticides, some bridging work Experimental recipe: species, duration, endpoints, limit doses 408 90-day oral; 413 90-day inhalation; 414 prenatal developmental; 443 extended one-generation reproductive toxicity (EOGRT); 420 acute oral fixed-dose; 471 bacterial reverse mutation (Ames)

EPA OPPTS/OCSPP 870 US pesticides (FIFRA) and some TSCA chemicals US chemical test methods, often parallel to OECD OCSPP 870.3100 90-day oral; 870.3700 developmental; 870.5100 Ames

ICH Human pharmaceuticals (with FDA and EMA) Which studies and when in development M3(R2) nonclinical timing; S5 reproductive toxicity; S1 carcinogenicity; S7A core safety pharmacology; S7B delayed ventricular repolarization

FDA/CDER US drugs and biologics US expectations on top of ICH, product-specific advice Repeat-dose species selection, impurity qualification, pediatric plans

FDA Redbook Food additives, color additives, some packaging Food-ingredient toxicity testing, not IND timing Subchronic rodent, reproductive, genotoxicity batteries for foods

EMA / CHMP EU medicines EU scientific guidelines, usually ICH-based Same ICH family, plus EU pediatric and environmental-risk expectations

GLP (FDA or OECD) Studies meant for regulatory submission How work is conducted and documented 21 CFR Part 58; OECD GLP Principles

Organisation for Economic Co-operation and Development (OECD) Test Guidelines are the lingua franca of chemical toxicology. If the question is a new herbicide’s 90-day oral systemic toxicity, OECD 408 (or the OCSPP twin) is the design language. If the same molecule is a drug candidate going to Center for Drug Evaluation and Research (CDER) for an investigational new drug (IND), ICH M3(R2) decides whether you need 14-day or 28-day or longer repeat-dose studies in two species , plus genotoxicity and safety pharmacology. FDA Redbook would be the wrong shelf entirely unless the agent is a food ingredient.

Environmental Protection Agency (EPA) Office of Prevention, Pesticides, and Toxic Substances / Office of Chemical Safety and Pollution Prevention (OPPTS/OCSPP) methods matter when the United States is registering a pesticide or demanding TSCA data. They often look like OECD studies with US numbering and occasional extra endpoints. International Council for Harmonisation (ICH) guidance is the pharmaceutical clock: M3(R2) maps nonclinical duration to intended clinical duration (a 2-week rodent/nonrodent package supporting up to 2 weeks in humans; 1-month toxicology supporting 1-month clinical; chronic rodent plus 9-month nonrodent for long-term US clinical use, with regional nuances). S5 is embryo-fetal and fertility design, S1 is carcinogenicity weight-of-evidence, S7A/S7B are the cardiovascular/respiratory/CNS core battery and the hERG/repolarization package.

European Medicines Agency (EMA) generally expects the ICH set, not a private EU animal recipe. What EMA may add is scientific advice, pediatric investigation needs, or environmental risk assessment—not a substitute for M3(R2).

Choosing the study that answers the question

Walk the question before you walk the animal room:

What decision will this study support? Hazard classification, occupational exposure limit, IND, food additive petition, pesticide registration, or a mechanistic publication?

What is the human (or ecological) route and duration? An 8-hour workplace aerosol is not a gavage bolus.

Which guideline already encodes that decision? OECD 413 or an acute inhalation TG for airborne local injury; OECD 414 or ICH S5 for embryo-fetal risk; OECD 443 when fertility, postnatal, and developmental neuro/immuno cohorts are in scope; OECD 471 when the question is bacterial mutagenicity, not cancer bioassay.

Is GLP required for that decision? Range-finding usually no; pivotal safety yes.

What will this study not answer? Ames does not measure clastogenicity. OECD 414 does not measure postnatal reproductive function the way 443 or a fertility study does. A 28-day oral rat does not replace a 9-month nonrodent for long clinical dosing.

Realistic exam scenario

A sponsor tells a contract laboratory, “Run a GLP OECD 408 so we can file a US IND next quarter for an oral small molecule.” The protocol writer should refuse that as a complete plan. OECD 408 is a 90-day oral chemical test guideline. An IND-enabling package is an ICH M3(R2) problem: repeat-dose toxicity in a rodent and a nonrodent at a duration matched to the proposed clinical trial, ICH S7A/S7B safety pharmacology, and a genotoxicity battery that typically includes OECD 471 plus in vitro and/or in vivo chromosome-damage assays under ICH S2 . Ninety oral days in one species, even under GLP, can be more animal use than M3 requires for a short first-in-human study and still miss cardiovascular safety pharmacology entirely.

If the same laboratory instead receives a new agricultural active for EU and US registration, OECD 408 plus 414 plus 443 (or the OCSPP equivalents), with EPA as a parallel driver, is the right family—and Redbook and S7B are the distractors.

Traps

Treating GLP as a substitute for choosing OECD versus ICH versus EPA.

Using FDA Redbook designs to enable a human drug trial.

Running OECD 414 and calling it EOGRT because fetuses were weighed.

Assuming EMA “does something completely different” from ICH for small-molecule timing.